Shares of Flexion Therapeutics Inc. (NASDAQ:FLXN) shot up 2.6% during mid-day trading on Friday . The stock traded as high as $15.74 and last traded at $15.51, with a volume of 81,607 shares traded. The stock had previously closed at $15.12.

Several equities analysts have commented on FLXN shares. Cantor Fitzgerald reiterated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, May 26th. Needham & Company LLC reiterated a “buy” rating and issued a $34.00 price objective (up from $28.00) on shares of Flexion Therapeutics in a report on Friday, May 27th. Zacks Investment Research upgraded shares of Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Wednesday. Janney Montgomery Scott reiterated a “buy” rating and issued a $30.00 price objective on shares of Flexion Therapeutics in a report on Friday, May 27th. Finally, BMO Capital Markets started coverage on shares of Flexion Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $35.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $32.56.

The company’s 50-day moving average is $15.09 and its 200-day moving average is $12.75. The firm’s market cap is $336.71 million.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.17. Analysts anticipate that Flexion Therapeutics Inc. will post ($2.84) EPS for the current fiscal year.

In related news, Director Samuel D. Colella acquired 6,778 shares of the company’s stock in a transaction on Monday, June 20th. The shares were acquired at an average cost of $13.84 per share, for a total transaction of $93,807.52. Following the purchase, the director now owns 3,435 shares in the company, valued at $47,540.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Samuel D. Colella acquired 25,504 shares of the company’s stock in a transaction on Tuesday, June 21st. The shares were bought at an average price of $13.71 per share, for a total transaction of $349,659.84. Following the completion of the purchase, the director now owns 3,435 shares in the company, valued at approximately $47,093.85. The disclosure for this purchase can be found here.

Other large investors have added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its stake in Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock worth $8,296,000 after buying an additional 59,866 shares during the last quarter. Schroder Investment Management Group boosted its stake in Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock worth $9,061,000 after buying an additional 81,500 shares during the last quarter. Jennison Associates boosted its stake in Flexion Therapeutics by 35.1% in the third quarter. Jennison Associates now owns 2,831,268 shares of the specialty pharmaceutical company’s stock worth $42,073,000 after buying an additional 736,261 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock worth $56,032,000 after buying an additional 76,487 shares during the last quarter.

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.